Clinical Trial Update: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults [Phase 3]

View source ↗

Summary

Phase 3 open-label study evaluating switching from optimized darunavir-containing regimens to a fixed-dose combination of elvitegravir/cobicistat/emtricitabine/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Darunavir (darunavir)
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) FDC (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2016-11-01